Abstract:
본 발명은 발효 옥수수 단백질 가수분해물로서, 상기 가수분해물에 포함된 유리 아미노산 총 중량에 대하여 글루탐산(Glutamic acid) 7.5 내지 20중량%, 알라닌(Alanine) 10.0 내지 30중량%, 메티오닌(Methionine) 2.5 내지 20중량%, 티로신(Tyrosine) 1.5 내지 20중량%, 시스테인(Cysteine) 0.1 내지 5.0중량%, 발린(Valine) 0.1 내지 8.0중량% 및 이소루신(Isoleucine) 0.1 내지 10.0 중량%을 함유하는 발효 옥수수 단백질 가수분해물 및 이의 제조방법을 제공한다. 본 발명의 발효 옥수수 단백질 가수분해물에 따르면, 식물성 단백질을 미생물 발효한 식물성 단백질 분해물을 이용하여 시상하부 식욕조절인자와 관계된 렙틴 수용체, POMC, NPY를 조정함으로써 식이섭취 감소, 체중감소 및 근육량 증가, 지질대사 및 당대사 개선에 의한 항비만 효과를 나타내므로, 항비만 목적을 가지는 기능성 소재, 건강식 제품 및 의약품에 적용 가능하다.
Abstract:
본 발명은 γ-PGA(Poly-γ-glutamic acid) 및 아이소플라본을 유효성분으로 포함하는 비만, 이상지방혈증, 지방간 또는 당뇨의 예방, 개선 또는 치료용 조성물에 관한 것이다. 본 발명은 비만, 이상지방혈증, 지방간 또는 당뇨의 예방 또는 치료에 대한 γ-PGA(Poly-γ-glutamic acid) 및 아이소플라본의 신규한 용도를 제시한다. 본 발명의 조성물은 지질대사와 당대사를 개선시킴으로써 비만, 고지혈 또는 지방간의 예방, 개선 또는 치료에 매우 유효하다. 본 발명 조성물에서의 유효성분으로서의 γ-PGA(Poly-γ-glutamic acid) 및 아이소플라본은 천연물이기 때문에 인체에 대하여 안전하다.
Abstract:
The invention relates to a method of preserving food products, in particular vegetable and soft fruit pieces, exposed to the risk of bacterial growth and rapid putrefaction processes, for storage in the frozen state. The essence of the freezing and glazing method with the use of an aqueous solution mist according to the present invention is that immediately before, during and/or after the initial freezing stage, the food product is UV-irradiated, preferably irradiated with UV-C light, and/or the moisture content of the air used for glazing is increased by a mist of an aqueous solution containing from 0.01 to 80% of flavouring agents and/or taste enhancing agents and/or 0.5 - 5 percent glycerine. The aqueous solution deposited in the form of glaze contains with respect to the food product weight from 0.01 to 1 percent of taste enhancing agents from the group of inosates and/or guanylates, preferably as sodium, calcium or potassium salts, and/or up to 20% of natural flavourings which differ in taste from the frozen food product.
Abstract:
The present invention relates to compositions comprising glutamic acid and/or glutamine, cysteine, riboflavin, succinic acid, fumaric acid, coenzyme Q10, niacin, optionally vitamin C, and/or prodrugs of these substances and/or salts of these substances. The compositions can be used as food supplement and/or medicament for prophylaxis or treatment of several disease conditions, in particular of hyperglycemia and related diseases or disorders. Consequently, the present invention is also directed to pharmaceutical compositions for the use in human and veterinary medicine as well as method of treatments of said diseases.
Abstract:
The invention relates to a foodstuff additive in particular for diets for a lasting adiposity therapy. The aim of said invention is to deliver a foodstuff additive for a lasting adiposity therapy for facilitating muscle-building and simultaneously fat-burning without excessive body training. For this purpose, the inventive foodstuff additive is based on a balanced aminoacid mixture whose quantitative ratio is nutritionally and physiologically optimal and which is supplemented with mineral salts containing 0.5-0.7g of calcium phosphate, 0.3-0.4 g of magnesium, 0.15-0.25 g of potassium, 0.04-0.06 of kelp which contains 7-8 mg iodine and oligoelements and from 0.15 to 0.25 g of lycopin-containing tomato extract. The totality of said indications is given in relation to 100 g of protein.
Abstract:
It has been found that high amounts of aspartate equivalents in combination with vitamin B12 and/or biotin, especially in relative absence of glutamate equivalents, improve the metabolism of ketobodies and/or lactate in a mammal's body, especially in diseased or traumatic conditions. As a result, levels of ketobodies and lactate can be decreased and unphysicologically high acidity normalised. Thus, it is an object of the invention to provide an enteral nutritional or a pharmaceutical composition for the treatment and/or prevention of disturbed ketone and lactate metabolism, i.e. elevated concentrations of ketone bodies, lactate and/or other organic acids and/or insufficient pH homeostasis, especially elevated concentrations of ketone bodies and/or lactate, in a mammal's blood, wherein the composition comprises high amounts of aspartate equivalents in combination with vitamin B12 and/or biotin, preferably in relative absence of glutamate equivalents.